SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

OCTO is trending due to its massive surge following news of a large private placement and a Worldcoin treasury strategy, with community members drawing comparisons to other high-flying stocks and debating whether it's a legitimate opportunity or a pump and dump. Bullish sentiment is fueled by the involvement of prominent figures like Dan Ives, while bears caution about potential dilution and an overinflated valuation. The stock's association with crypto and treasury strategies is contributing to the intense speculation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following news of a multi-billion dollar AI infrastructure deal with Microsoft, significantly exceeding the company's current market cap and revenue projections. The community is discussing the potential for substantial revenue growth and future partnerships, while some caution against potential short-term volatility. This deal underscores the increasing importance of AI infrastructure and positions NBIS as a key player in the sector.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position as the top meme coin on the Bitcoin network, emphasizing its fair launch and strong community. Discussions highlight its potential to onboard new users to Bitcoin and its unique role within the Bitcoin ecosystem. Some community members are anticipating a significant price increase, while also pointing to the backing from C2 Blockchain.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies amidst a leadership transition, with some expressing concerns about the former leader while others remain bullish. The focus is on community strength and accumulation, with many emphasizing long-term potential and the unique aspect of being an ETF on the Solana blockchain. Despite some negativity, there's a strong sense of loyalty and anticipation for future growth.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

The Skycoin Platform is the most advanced blockchain platform in the world. Developed by early contributors to both Bitcoin and Ethereum, Skycoin’s platform is completely secure, infinitely scalable, and ISP independent. It uses its own specific distributed consensus algorithm, called Obelisk, instead of other commonly used algorithms like proof of work (POW) and proof of stake (POS). Obelisk uses the concept of ‘web of trust dynamics’ which distributes influence over the network and makes consensus decisions depending upon the influence score of each node. Each node subscribes to a select number of other network nodes, and the density of a node’s network of subscribers determines its influence on the network.  Skycoin is very fast. With transaction speeds close to 2 seconds and no transaction fees it can rival any other cryptocurrency on the market as a payment method. The transaction costs of Skycoin are covered by Coin Hours. This is value paid to Skycoin holders for each hour they hold a Skycoin. Skycoin is against charging transaction costs and mining incentives as it only drives up the costs of the network. The biggest benefit of Skycoin is that it is energy efficient due to the Web-of-Trust social proof. It can even run on a 30-watt cell phone processor making it great for mobile payments. Centralization becomes less of an issue when anyone can participate in the blockchain. Sia stores tiny pieces of your files on dozens of nodes across the globe. This eliminates any single point of failure and ensures highest possible uptime, on par with other cloud storage providers.  A major goal of Skycoin is to promote actual usage of cryptocurrency rather than speculation. Skywire, the flagship application of Skycoin, has the ambitious goal of decentralizing the internet at the hardware level and is about to begin the testnet in April. However, this is just one of the many facets of the Skycoin ecosystem. Skywire will not only provide decentralized bandwidth but also storage and computation, completing the holy trinity of commodities essential for the new internet.  Skycoin also has its own ICO platform called Fiber, their own deterministic programming language, CX, derived from Golang, a private decentralized messenger system called Sky-Messenger, and a decentralized social media platform, BBS.  Here is another way to think of Skycoin: An open-source, community-owned, hardware-based peer to peer internet designed from first principles and leveraging the incentive system of the blockchain.

Skycoin

Skycoin ($SKY.X) is trending as the community discusses its potential, solid tech, and Skywire backing. Some believe it is undervalued and a sleeping giant, while others warn of potential pump-and-dump schemes. Discussion includes its limited supply and comparisons to competitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Inc. (CERT) Q2 Earnings Miss Estimates

Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth

Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Certara Stock We Don't?

Investors need to pay close attention to CERT stock based on the movements in the options market lately.

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?

Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

Is AI changing FDA-biopharma dynamics?

The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&amp;P 500 rose 0.79%, and the Nasdaq Composite climbed 0.64%. However, all three major averages were in the red at one point during the trading session. Despite this, the stocks making moves on market news continued to captivate investors with their dynamic performances and strategic advancements. In this article, we will take a look at the 6 best stocks that were making moves on market news with their groundbreaking innovations and strategic advancements.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/quantum-biopharma-expands-reach-with-new-unbuzzd-launch-and-cutting-edge-ms-clinical-study/">This Low-Float Biotech Stock is making waves with an advanced MS diagnostic tool</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>1. Recursion Pharmaceuticals (RXRX)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.34 Billion&nbsp;&nbsp;Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages artificial intelligence and automation to discover and develop novel therapeutics across a wide range of diseases.First Patient Dosed: Recursion Pharmaceuticals has recently announced the dosing of the first patient in its early-stage study of REC-3565 for treating relapsed or refractory B-cell lymphomas, which marks a significant clinical milestone.Unique Mechanism: REC-3565 has a unique mechanism of action that reduces the risk of drug-drug interactions and hyperbilirubinemia, making it potentially safer and more effective.Preclinical Success: Preclinical studies showed durable tumor regressions with REC-3565, both as monotherapy and in combination with a BTK inhibitor, which indicates strong clinical efficacy.Industry Collaborations: The company has partnerships with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi, which provides it with additional resources and market access.FDA Policy Shift: The FDA has also announced to phase out some animal testing requirements for monoclonal antibodies, which benefits RXRX’s AI-driven platform.Stock Performance:Recursion Pharmaceuticals has shown strong weekly performance with a 45.26% gain. However, it has underperformed in the month and year, with declines of 15.69% and 31.43%, respectively.<h3>2. Certara (CERT)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.29 Billion&nbsp;&nbsp;Certara (NASDAQ: CERT) provides biosimulation software and technology-driven solutions to improve the drug development process, helping biopharma companies optimize clinical outcomes.Strong First Quarter Financial Results: On April 14, Certara reported preliminary first-quarter 2025 financial results.&nbsp; The company reported a 10% revenue growth to $106.0 million compared to the first quarter of 2024, with software revenue growing by 18% to $46.4 million.Bookings Growth: The company’s bookings increased by 12% to $118 million, with software bookings growing by 22% to 40.6 million.Adjusted EBITDA Growth: Adjusted EBITDA is expected to be in the range of $33 million to $35 million, representing a 13-20% growth compared to the first quarter of 2024.Reiteration of Full-Year Guidance: Certara reiterated its full-year 2025 guidance, projecting revenue in the range of $415 million to 425 million, an adjusted EBITDA margin of 30-32%, and adjusted diluted earnings per share of 42 to 46 cents.Stock Repurchase Authorization: The Board of Directors authorized a stock repurchase program of up to $100 million, reflecting confidence in the company’s strategy and financial performance.Non-Animal Navigator Launch: Certara launched its Non-Animal Navigator solution to help biopharmaceutical companies reduce reliance on animal testing by offering strategic regulatory advice, integrated preclinical development plans, and optimized AI-enabled modeling tools.Industry Adoption: The growing industry adoption of new approach methodologies (NAMs) like AI-enabled biosimulation supports Certara’s strategic focus and enhances its competitive position.Stock Performance:Certara has had a robust week with a 57.18% increase. However, it has faced losses over longer periods, including a 19.50% decline in performance year-to-date.<h3>3. United States Antimony (UAMY)&nbsp;&nbsp;</h3>Market Cap as of April 15: $377.72 Million&nbsp;&nbsp;United States Antimony (NYSEAMERICAN: UAMY) is involved in the mining, production, and sale of antimony and zeolite products, which are used in flame retardants, batteries, and chemical applications.Lease/Option Purchase Agreement: United States Antimony has executed a new lease/option purchase agreement with an experienced prospector in Wasilla, Alaska, for lands adjacent to existing leased and staked claims, with new claims and leases totaling 17,900 acres in the Fairbanks area and 3,840 acres near Stibnite Creek.Exploration Focus: Plans to begin high-grade stibnite exploration and mining operations in early May in the Fairbanks area. Management aims to extract antimony ore from its own mining claims in Alaska to Montana by Q3 2025.Antimony Production and Global Supply: China is the world’s top producer of antimony, but its output has been declining over the past decade, making it difficult to meet global needs without new sources. Furthermore, Antimony prices have surged due to China’s export ban, which began in December 2024.Montana Smelters: The company operates two smelters in Montana with capacities of 3,840tpa and 2,400tpa for antimony processing.Stock Performance:United States Antimony has demonstrated exceptional growth across various periods, including a strong weekly gain of 66.92%. It has also seen a remarkable year-over-year growth of 1,239.51%.&nbsp;Read Now: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/tech/u-power-makes-waves-at-bangkok-motor-show-with-groundbreaking-battery-swap-demo/">Electric Vehicle Player Is Making Waves With Groundbreaking Battery Swapping Technology</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>4. Janover (JNVR)&nbsp;&nbsp;</h3>Market Cap as of April 15: $106.54 Million&nbsp;&nbsp;Janover (NASDAQ: JNVR) provides online platforms for commercial real estate and small business loans, connecting borrowers with lenders using data-driven digital solutions.New Treasury Strategy: Janover announced a new treasury policy on April 4, 2025, to accumulate crypto assets, starting with Solana (SOL). This strategy aligns with the company’s goal of providing investors economic exposure to SOL.Significant SOL Purchases: Janover made substantial purchases of Solana (SOL) tokens, totaling $21.2 million across three transactions. These purchases have brought the company’s total SOL holdings to 163,651.7.Staking and Revenue Generation: The company will begin staking its SOL position immediately, generating revenue while supporting the Solana network. Staking rewards are also planned to be reinvested, which will further enhance cryptoasset holdings.Recent Financing Round: Janover has also raised $42 million in a financing round from investors including Pantera Capital and Kraken. These funds are specifically allocated for acquiring digital assets.Stock Performance:Janover has seen explosive growth, with a week-over-week performance of 130.20% and a remarkable 1707.42% increase in the month.<h3>5. Skye Bioscience (SKYE)</h3>Market Cap as of April 15: $82.40 MillionSkye Bioscience (NASDAQ: SKYE) is a pharmaceutical company focused on developing cannabinoid-derived molecules to treat glaucoma and other diseases with unmet medical needs.Significant Weight Loss in Preclinical Study: On April 15, Skye Bioscience announced over 30% weight loss in a diet-induced obesity model when nimacimab was combined with tirzepatide, which showcases its strong efficacy and potential as a combination therapy.Comparable Efficacy to Monlunabant and Tirzepatide: Nimacimab alone achieved 23.5% weight loss, comparable to other leading obesity drugs like tirzepatide and monlunabant, which indicates robust monotherapy potential.Differentiated Mechanism: Nimacimab’s non-competitive allosteric binding to the CB1 receptor provides a differentiated mechanism compared to monlunabant and has potentially fewer neuropsychiatric side effects.Superior Potency in High Agonist Conditions: In vitro data showed nimacimab’s potency remained stable under high agonist conditions, while monlunabant’s effectiveness was significantly impacted, which indicates superior performance in disease states like obesity.Phase 2a Data: Top-line data from the Phase 2a CBeyond study is expected in late Q3/early Q4 2025, which will provide investors with near-term clinical validation of nimacimab’s efficacy.Focus on Metabolic Health: Skye’s focus on developing next-generation molecules for metabolic health disorders aligns with the growing demand for effective obesity treatments in the market.First-In-Class Therapeutic Potential: Nimacimab’s mechanism of action as a negative allosteric modulating antibody for CB1 inhibition positions it as a first-in-class therapeutic with clinical and commercial differentiation.Stock Performance:Skye Bioscience has had a mixed performance, with a significant weekly gain of 143.32% but a modest monthly gain of only 15.41%.<h3>6. Aerovate Therapeutics (AVTE)</h3>Market Cap as of April 15: $79.12 MillionAerovate Therapeutics (NASDAQ: AVTE) is a biotechnology company developing inhaled therapies for rare cardiopulmonary diseases, with a lead candidate targeting pulmonary arterial hypertension.Expected Cash Dividend: Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 million to $69.6 million in the aggregate, based on its estimated net cash immediately prior to the closing of its merger with Jade Biosciences, which was announced on October 30, 2024.Merger Status: The Merger remains subject to approval by Aerovate’s stockholders and other closing conditions. The special meeting for stockholder approval is scheduled for April 16, 2025, with the Closing expected on or about April 28, 2025.Dividend Declaration: The official declaration of the Cash Dividend is subject to approval by the Aerovate board of directors and is expected to be announced later this month.Payment Details: The dividend will be paid with an estimated $2.40 per share based on 28,985,019 shares outstanding as of April 9, 2025. The payment date is scheduled for April 29, 2025.Purpose of Merger: The merger will combine Aerovate’s expertise in rare cardiopulmonary diseases with Jade’s focus on developing best-in-class therapies for autoimmune diseases. This combination is expected to create a robust pipeline and enhanced capabilities to address critical unmet medical needs.Stock Performance:Aerovate Therapeutics has exhibited extraordinary performance, with a week-over-week gain of 2914.67% and a month-over-month gain of 2975.95%, making it a standout performer among the stocks listed.<h3>Conclusion</h3>As we conclude our review of these promising companies, it’s clear that these stocks making moves on market news are not just fleeting trends but represent substantial investment opportunities. Each company discussed here is leveraging cutting-edge technology, strategic partnerships, and market shifts to propel their businesses forward, making them standout choices for discerning investors.&nbsp; &nbsp;Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/top-4-stocks-poised-for-big-gains/">4 Stocks Poised for Big Gains Amid Major Transformations</a> &nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>.Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Others

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.

Current Price	$10.70
Prev Close	$10.52
Open	$10.61
Dividend Yield	0.00%
50-Day Moving Average	$10.81
Beta	1.13
Avg. Volume	1.33M
PE Ratio	212.96

52-Week High	$15.69
52-Week Low	$8.64
Market Capitalization	$1.69B
EPS (Annual)	-$0.0751
Price to Book	1.58
Revenue Per Employee	$249,125.48
Enterprise Value/EBITDA	N/A

CERT
Certara Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CERT News

CERT Certara Inc